What we do
Equity products
Technology Transfer
European Angels Fund (EAF) - Co-investments with Business Angels
Venture capital
The Social Impact Accelerator (SIA)
Lower mid-market
Mezzanine Facility for Growth
Pan-European Venture Capital Fund(s)-of-Funds programme
EFSI Equity instrument
Single EU Equity Financial Instrument
COSME - Equity Facility for Growth
InnovFin Equity
Private equity secondary market transactions
EIF-NPI Equity Platform
Debt products
AGRI Guarantee Facility
Credit enhancement
Cultural and Creative Sectors Guarantee Facility (CCS GF)
ENSI - Securitisation Initiative
Erasmus+ Master Loan Guarantee Facility
EREM debt products
Single EU Debt Financial Instrument
COSME - Loan Guarantee Facility
InnovFin SME Guarantee Facility
The SME Initiative
The SME Initiative Bulgaria
The SME Initiative Finland
The SME Initiative Italy
The SME Initiative Malta
The SME Initiative Romania
The SME Initiative Spain
Inclusive finance
EaSI Financial Instruments
EaSI Capacity Building Investments Window
EaSI Guarantee Instrument
European Progress Microfinance Facility
Entrepreneurs supported through Progress Microfinance
European Fund for Strategic Investments (EFSI)
How does EIF contribute to EFSI
How to apply for EFSI financing
Regional Development - Country and sector-specific initiatives
Baltic Innovation Fund (BIF)
Competitiveness Fund-of-Funds for SMEs in Romania
Regional Fund-of-Funds Romania
La Financière Région Réunion
Deep and Comprehensive Free Trade Area Initiative East Guarantee Facility (DCFTA)
Dutch Venture Initiative (DVI-II)
Dutch Growth Co-Investment Programme
European Recovery Programme (ERP)
ERP-EIF Co-Investment Growth Facility
ESIF Fund-of-Funds Czech Republic
ESIF Fund-of-Funds Greece
The Silesia EIF Fund of Funds
EstFund
FOSTER TPE-PME Occitanie
Greater Anatolia Guarantee Facility (GAGF)
G43 - Anatolian Venture Capital Fund Project
JEREMIE
LfA-EIF Facility
Luxembourg Future Fund (LFF)
Mezzanine 'Fund of Fund' for Germany (MDD)
Polish Growth Fund of Funds (PGFF)
Swedish Venture Initiative (SVI)
Turkish Growth and Innovation Fund (TGIF)
Scottish-European Growth Co-Investment Programme
Slovene Equity Growth Investment Programme (SEGIP)
The EIB Group Risk Enhancement Mandate (EREM)
Western Balkans Enterprise Development & Innovation Facility II (WB EDIF II)

How EFSI benefits SMEs in Europe - ING case study: Flen Pharma (Luxembourg), Medical device company

image

It was during a barbecue, at which the daughter of one of his friends was badly burned, that the idea came to Philippe Sollie, pharmacist by profession, to develop a new type of wound care product. The little girl was allergic to a large number of ingredients contained in the traditional creams, so Philippe developed a simple to use, but extremely effective gel, labelled ‘Flamigel®’, which keeps the wound moist. This has the advantage of continuously cleaning the wound, speeding up the healing process and avoiding any scar tissue.

After having filed a patent, Philippe encountered huge success with his innovative idea. Building on his passion for pharmaceutical research and his motivation to contribute to a better quality of life, he developed a whole range of medical devices based on the same principles. With ‘Flaminal® Hydro’ and ‘Flaminal® Forte’, which he has been distributing first in Europe and later across the world, from his base in Esch-sur-Alzette, Luxembourg, he created a new product class: the ‘Enzyme Alginogel®’. It combines two principles of fast and efficient wound healing by achieving a bacterial balance (using enzymes) and a moisture balance (using alginates) in the wound. Moreover, ‘Flaminal®’, unlike other wound care gels, can be used on all tissues and throughout all phases of wound healing, making the life of wound experts and their patients easier.

To further expand his activity, Philippe secured an EU-guaranteed loan provided by ING Luxembourg and backed by EIF under the Investment Plan for Europe. This EU initiative aims to generate new investments by facilitating access to finance for small and medium-sized enterprises. Philippe has used part of his loan to open a franchise in the United Kingdom (Flen Health) allowing for the creation of its own network of distributors. Furthermore, Philippe is planning to use the other part of the loan to hire two additional researchers and invest in the research and development of his products.

Today, Philippe employs around 75 staff and continues to offer through ‘Flen Pharma’ and ‘Flen Health’ a new class of wound healing products, reducing pain and trauma after injury.

Company: Flen Pharma (Luxembourg)

Type of business: Medical device company

EIF financing: InnovFin SMEG, EFSI

For further information abiout EIF intermediaries in Luxembourg, please refer to: http://www.eif.org/what_we_do/where/lu


 
 

Copyright ©

 European Investment Fund 2017 – The European Investment Fund is not responsible for the content of external internet sites.